Venus Medtech Stock Analysis
| VMTHF Stock | USD 0.27 0.00 0.00% |
Venus Medtech holds a debt-to-equity ratio of 0.015. Venus Medtech's financial risk is the risk to Venus Medtech stockholders that is caused by an increase in debt.
Asset vs Debt
Equity vs Debt
Venus Medtech's liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Venus Medtech's cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Venus Pink Sheet's retail investors understand whether an upcoming fall or rise in the market will negatively affect Venus Medtech's stakeholders.
For many companies, including Venus Medtech, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Venus Medtech, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Venus Medtech's management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Given that Venus Medtech's debt-to-equity ratio measures a Company's obligations relative to the value of its net assets, it is usually used by traders to estimate the extent to which Venus Medtech is acquiring new debt as a mechanism of leveraging its assets. A high debt-to-equity ratio is generally associated with increased risk, implying that it has been aggressive in financing its growth with debt. Another way to look at debt-to-equity ratios is to compare the overall debt load of Venus Medtech to its assets or equity, showing how much of the company assets belong to shareholders vs. creditors. If shareholders own more assets, Venus Medtech is said to be less leveraged. If creditors hold a majority of Venus Medtech's assets, the Company is said to be highly leveraged.
Venus Medtech is overvalued with Real Value of 0.24 and Hype Value of 0.27. The main objective of Venus Medtech pink sheet analysis is to determine its intrinsic value, which is an estimate of what Venus Medtech is worth, separate from its market price. There are two main types of Venus Medtech's stock analysis: fundamental analysis and technical analysis.
The Venus Medtech pink sheet is traded in the USA on PINK Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Venus Medtech's ongoing operational relationships across important fundamental and technical indicators.
Venus |
Venus Pink Sheet Analysis Notes
About 22.0% of the company outstanding shares are owned by insiders. The company has Price to Book (P/B) ratio of 1.08. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. Venus Medtech recorded a loss per share of 0.13. The entity had not issued any dividends in recent years. Venus Medtech Inc. develops and commercializes transcatheter heart valve medical devices in Mainland China and internationally. The company was founded in 2009 and is headquartered in Hangzhou, the Peoples Republic of China. Venus Medtech operates under Medical Devices classification in the United States and is traded on OTC Exchange. It employs 905 people.The quote for Venus Medtech is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. For more information please call the company at 86 57 1877 72180 or visit https://www.venusmedtech.com.Venus Medtech Investment Alerts
| Venus Medtech generated a negative expected return over the last 90 days | |
| Venus Medtech has some characteristics of a very speculative penny stock | |
| The company reported the revenue of 415.86 M. Net Loss for the year was (373.64 M) with profit before overhead, payroll, taxes, and interest of 324.34 M. | |
| Venus Medtech has accumulated about 2.96 B in cash with (456.92 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.75, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 22.0% of the company outstanding shares are owned by insiders |
Venus Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 855.6 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Venus Medtech's market, we take the total number of its shares issued and multiply it by Venus Medtech's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Venus Profitablity
The company has Profit Margin (PM) of (1.19) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.18) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.18.Technical Drivers
As of the 7th of February, Venus Medtech has the Risk Adjusted Performance of (0.12), variance of 1.66, and Coefficient Of Variation of (642.52). In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Venus Medtech, as well as the relationship between them. Please validate Venus Medtech market risk adjusted performance, variance, as well as the relationship between the Variance and skewness to decide if Venus Medtech is priced more or less accurately, providing market reflects its prevalent price of 0.27 per share. As Venus Medtech appears to be a penny stock we also recommend to double-check its information ratio numbers.Venus Medtech Price Movement Analysis
The output start index for this execution was twenty-nine with a total number of output elements of thirty-two.
Venus Medtech Predictive Daily Indicators
Venus Medtech intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Venus Medtech pink sheet daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Venus Medtech Forecast Models
Venus Medtech's time-series forecasting models are one of many Venus Medtech's pink sheet analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Venus Medtech's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.Venus Medtech Debt to Cash Allocation
Many companies such as Venus Medtech, eventually find out that there is only so much market out there to be conquered, and adding the next product or service is only half as profitable per unit as their current endeavors. Eventually, the company will reach a point where cash flows are strong, and extra cash is available but not fully utilized. In this case, the company may start buying back its stock from the public or issue more dividends.
Venus Medtech has accumulated 70.78 M in total debt with debt to equity ratio (D/E) of 0.02, which may suggest the company is not taking enough advantage from borrowing. Venus Medtech has a current ratio of 16.16, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Venus Medtech until it has trouble settling it off, either with new capital or with free cash flow. So, Venus Medtech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Venus Medtech sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Venus to invest in growth at high rates of return. When we think about Venus Medtech's use of debt, we should always consider it together with cash and equity.Venus Medtech Assets Financed by Debt
Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Venus Medtech's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Venus Medtech, which in turn will lower the firm's financial flexibility.About Venus Pink Sheet Analysis
Pink Sheet analysis is the technique used by a trader or investor to examine and evaluate how Venus Medtech prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Venus shares will generate the highest return on investment. We also built our pink sheet analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Pink Sheet such as Venus Medtech. By using and applying Venus Pink Sheet analysis, traders can create a robust methodology for identifying Venus entry and exit points for their positions.
Venus Medtech Inc. develops and commercializes transcatheter heart valve medical devices in Mainland China and internationally. The company was founded in 2009 and is headquartered in Hangzhou, the Peoples Republic of China. Venus Medtech operates under Medical Devices classification in the United States and is traded on OTC Exchange. It employs 905 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our pink sheet analysis tools, you can find out how much better you can do when adding Venus Medtech to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Piotroski F Score Now
Piotroski F ScoreGet Piotroski F Score based on the binary analysis strategy of nine different fundamentals |
| All Next | Launch Module |
Complementary Tools for Venus Pink Sheet analysis
When running Venus Medtech's price analysis, check to measure Venus Medtech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Venus Medtech is operating at the current time. Most of Venus Medtech's value examination focuses on studying past and present price action to predict the probability of Venus Medtech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Venus Medtech's price. Additionally, you may evaluate how the addition of Venus Medtech to your portfolios can decrease your overall portfolio volatility.
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments |